Consistently, the level of phosphorylated ERK, a downstream target of these three drugs, had a notable positive correlation with ST6GALNAC5 expression in PCa cells, implying an adjunctive ST6GALNAC5-targeted therapy for PCa patients. This evidence concerns the gene ST6GALNAC5 and posterior cortical atrophy.